Anger resurfaces over UK medicine rebate levels

Industry has renewed its criticism of the UK government after the publication of new terms for the statutory scheme for branded medicines.

According to the Association of the British Pharmaceutical Industry (ABPI), the terms will maintain sales rebates at levels which have damaged the UK’s international standing with global life science companies.

"The government has consistently said it wants to support the international competitiveness of UK-based life sciences"The announcement follows the agreement in mid-November of a new Voluntary Scheme for Pricing, Access and Growth (VPAG), a negotiated alternative arrangement which companies can opt into over the Statutory Scheme.